Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Prospects for vaccine prevention of meningococcal infection.

Harrison LH.

Clin Microbiol Rev. 2006 Jan;19(1):142-64. Review.

2.

Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meissner HC, Baker CJ, Messonnier NE; Centers for Disease Control and Prevention (CDC)..

MMWR Recomm Rep. 2013 Mar 22;62(RR-2):1-28.

3.
4.
5.

Evolving meningococcal immunization strategies.

Sáfadi MA, Bettinger JA, Maturana GM, Enwere G, Borrow R; Global Meningococcal Initiative..

Expert Rev Vaccines. 2015 Apr;14(4):505-17. doi: 10.1586/14760584.2015.979799. Epub 2014 Dec 10. Review.

PMID:
25494168
6.

Changes in the Population Structure of Invasive Neisseria meningitidis in the United States After Quadrivalent Meningococcal Conjugate Vaccine Licensure.

Wang X, Shutt KA, Vuong JT, Cohn A, MacNeil J, Schmink S, Plikaytis B, Messonnier NE, Harrison LH, Clark TA, Mayer LW.

J Infect Dis. 2015 Jun 15;211(12):1887-94. doi: 10.1093/infdis/jiu842. Epub 2015 Jan 2.

PMID:
25556253
7.

Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.

Snape MD, Perrett KP, Ford KJ, John TM, Pace D, Yu LM, Langley JM, McNeil S, Dull PM, Ceddia F, Anemona A, Halperin SA, Dobson S, Pollard AJ.

JAMA. 2008 Jan 9;299(2):173-84. doi: 10.1001/jama.2007.29-c. Erratum in: JAMA. 2011 Mar 16;305(11):1096.

PMID:
18182599
8.

Safety and immunogenicity of meningococcal ACWY CRM197-conjugate vaccine in children, adolescents and adults in Russia.

Ilyina N, Kharit S, Namazova-Baranova L, Asatryan A, Benashvili M, Tkhostova E, Bhusal C, Arora AK.

Hum Vaccin Immunother. 2014;10(8):2471-81. doi: 10.4161/hv.29571.

9.

A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.

McVernon J, Nolan T, Richmond P, Reynolds G, Nissen M, Lambert SB, Marshall H, Papa T, Rehm C.

Pediatr Infect Dis J. 2012 Jan;31(1):e15-23. doi: 10.1097/INF.0b013e31823e1e34.

PMID:
22094636
10.

Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.

Perrett KP, Snape MD, Ford KJ, John TM, Yu LM, Langley JM, McNeil S, Dull PM, Ceddia F, Anemona A, Halperin SA, Dobson S, Pollard AJ.

Pediatr Infect Dis J. 2009 Mar;28(3):186-93. doi: 10.1097/INF.0b013e31818e037d.

PMID:
19209097
11.

Meningococcal quadrivalent (serogroups A, C, W135 and Y) tetanus toxoid conjugate vaccine (Nimenrix™).

Croxtall JD, Dhillon S.

Drugs. 2012 Dec 24;72(18):2407-30. doi: 10.2165/11209580-000000000-00000. Review.

PMID:
23231026
12.

Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use - Advisory Committee on Immunization Practices (ACIP), 2010.

Centers for Disease Control and Prevention (CDC)..

MMWR Morb Mortal Wkly Rep. 2010 Mar 12;59(9):273.

13.

Meningococcal vaccines: current issues and future strategies.

Cohn AC, Harrison LH.

Drugs. 2013 Jul;73(11):1147-55. doi: 10.1007/s40265-013-0079-2. Review.

PMID:
23839656
14.

A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial.

Block SL, Szenborn L, Daly W, Jackowska T, D'Agostino D, Han L, Dull PM, Smolenov I.

Vaccine. 2015 May 15;33(21):2500-10. doi: 10.1016/j.vaccine.2015.03.001. Epub 2015 Mar 17.

PMID:
25795256
15.

[Meningococcal vaccines: from polysaccharide to conjugate vaccines].

Cohen R, Levy C.

Arch Pediatr. 2012 Sep;19 Suppl 2:S61-4. doi: 10.1016/S0929-693X(12)71275-7. French.

PMID:
22883368
16.

Review of meningococcal vaccines with updates on immunization in adults.

Zahlanie YC, Hammadi MM, Ghanem ST, Dbaibo GS.

Hum Vaccin Immunother. 2014;10(4):995-1007. Epub 2014 Feb 5. Review.

17.

Impact of meningococcal C conjugate vaccine in the UK.

Balmer P, Borrow R, Miller E.

J Med Microbiol. 2002 Sep;51(9):717-22. Review.

PMID:
12358061
18.

Challenges for development of meningococcal vaccines in infants and children.

Deasy A, Read RC.

Expert Rev Vaccines. 2011 Mar;10(3):335-43. doi: 10.1586/erv.11.3. Review.

PMID:
21434801
19.

Safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2- to 10-year-old human immunodeficiency virus-infected children.

Siberry GK, Warshaw MG, Williams PL, Spector SA, Decker MD, Jean-Philippe P, Yogev R, Heckman BE, Manzella A, Roa J, Nachman S, Lujan-Zilbermann J; IMPAACT P1065 Protocol Team..

Pediatr Infect Dis J. 2012 Jan;31(1):47-52. doi: 10.1097/INF.0b013e318236c67b.

20.

Evaluation of serogroup C and ACWY meningococcal vaccine programs: projected impact on disease burden according to a stochastic two-strain dynamic model.

Vickers DM, Anonychuk AM, De Wals P, Demarteau N, Bauch CT.

Vaccine. 2015 Jan 1;33(1):268-75. doi: 10.1016/j.vaccine.2013.09.034. Epub 2013 Oct 6.

Supplemental Content

Support Center